DGIdb - ROFECOXIB Drug Record

ROFECOXIB chembl:CHEMBL122

Alternate Names:

ROFECOXIB
M01AH02
MK-966
MK-0966
VIOXX
MK0966
4-[4-(METHYLSULFONYL)PHENYL]-3-PHENYL-2(5H)-FURANONE
CEOXX®
VIOXX®
3-PHENYL-4-[4-(METHYLSULFONYL)PHENYL]-2(5H)-FURANONE
CEOXX
MK 966
4-[4-(METHYLSULFONYL)PHENYL]-3-PHENYLFURAN-2(5H)-ONE
chembl:CHEMBL122
pubchem.compound:5090
drugbank:00533
chemidplus:162011-90-7
rxcui:232158

Drug Info:

FDA Approval	withdrawn
Drug Class	small molecule
Drug Indications	NSAID

(5 More Sources)

Publications:

Brzozowski et al., 2006, Prostaglandin/cyclooxygenase pathway in ghrelin-induced gastroprotection against ischemia-reperfusion injury., J. Pharmacol. Exp. Ther.
Brzozowska et al., 2004, Healing of chronic gastric ulcers in diabetic rats treated with native aspirin, nitric oxide (NO)-derivative of aspirin and cyclooxygenase (COX)-2 inhibitor., J. Physiol. Pharmacol.
Pyrko et al., 2006, Downregulation of survivin expression and concomitant induction of apoptosis by celecoxib and its non-cyclooxygenase-2-inhibitory analog, dimethyl-celecoxib (DMC), in tumor cells in vitro and in vivo., Mol. Cancer
Konturek et al., 2003, Influence of COX-2 inhibition by rofecoxib on serum and tumor progastrin and gastrin levels and expression of PPARgamma and apoptosis-related proteins in gastric cancer patients., Dig. Dis. Sci.
Grosser T, 2009, Variability in the response to cyclooxygenase inhibitors: toward the individualization of nonsteroidal anti-inflammatory drug therapy., J Investig Med
Lee YS et al., 2006, Genetically mediated interindividual variation in analgesic responses to cyclooxygenase inhibitory drugs., Clin Pharmacol Ther
Ashok et al., 2011, Selective cyclooxygenase-2 (COX-2) inhibitors and breast cancer risk., Breast
Langman et al., 1999, Adverse upper gastrointestinal effects of rofecoxib compared with NSAIDs., JAMA
Malmstrom et al., 1999, Comparison of rofecoxib and celecoxib, two cyclooxygenase-2 inhibitors, in postoperative dental pain: a randomized, placebo- and active-comparator-controlled clinical trial., Clin Ther
Chakraborti et al., 2010, Progress in COX-2 inhibitors: a journey so far., Curr. Med. Chem.
Pascucci, 1999, COX-2-specific inhibition: implications for clinical practice., J Am Osteopath Assoc
Chen et al., 2002, TTD: Therapeutic Target Database., Nucleic Acids Res.
Matheson et al., 2001, Rofecoxib: a review of its use in the management of osteoarthritis, acute pain and rheumatoid arthritis., Drugs
Hawkey et al., 2000, Comparison of the effect of rofecoxib (a cyclooxygenase 2 inhibitor), ibuprofen, and placebo on the gastroduodenal mucosa of patients with osteoarthritis: a randomized, double-blind, placebo-controlled trial. The Rofecoxib Osteoarthritis Endoscopy Multinational Study Group., Arthritis Rheum.
Baron et al., 2008, Cardiovascular events associated with rofecoxib: final analysis of the APPROVe trial., Lancet
Ehrich et al., 1999, Effect of specific COX-2 inhibition in osteoarthritis of the knee: a 6 week double blind, placebo controlled pilot study of rofecoxib. Rofecoxib Osteoarthritis Pilot Study Group., J. Rheumatol.
Ebert et al., 2005, Protective role of heat shock protein 27 in gastric mucosal injury., J. Pathol.

ROFECOXIB PTGS2

Interaction Score: 1.76

Interaction Types & Directionality:

inhibitor (inhibitory)

Interaction Info:

Trial Name rofecoxib,Vioxx

Novel drug target Established target

Specific Action of the Ligand Inhibition

PMIDs:
19602986 16678543 20724158 10580458 10566562 20166930 10643177 11752352 11398914 10693877 18922570 10555907

Sources:
TdgClinicalTrial ChemblInteractions GuideToPharmacology PharmGKB TTD
ROFECOXIB GHRL

Interaction Score: 1.52

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
16868036

Sources:
NCI
ROFECOXIB IL10

Interaction Score: 1.07

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
15613743

Sources:
NCI
ROFECOXIB BIRC5

Interaction Score: 0.76

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
16707021 14627349

Sources:
NCI
ROFECOXIB HSPB1

Interaction Score: 0.59

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
16041694

Sources:
NCI
ROFECOXIB BAX

Interaction Score: 0.38

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
14627349

Sources:
NCI
ROFECOXIB ALDH1A1

Interaction Score: 0.02

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
None found

Sources:
DTC

TdgClinicalTrial: ROFECOXIB
- Version: January-2014
Alternate Names:

Drug Info:

Drug Indications NSAID

Drug Class small molecule

FDA Approval withdrawn

Publications:

NCI: ROFECOXIB

Version: 14-September-2017

Alternate Names:

C1832 NCI drug code

Drug Info:

Publications:

Brzozowska et al., 2004, Healing of chronic gastric ulcers in diabetic rats treated with native aspirin, nitric oxide (NO)-derivative of aspirin and cyclooxygenase (COX)-2 inhibitor., J. Physiol. Pharmacol.

Pyrko et al., 2006, Downregulation of survivin expression and concomitant induction of apoptosis by celecoxib and its non-cyclooxygenase-2-inhibitory analog, dimethyl-celecoxib (DMC), in tumor cells in vitro and in vivo., Mol. Cancer

Brzozowski et al., 2006, Prostaglandin/cyclooxygenase pathway in ghrelin-induced gastroprotection against ischemia-reperfusion injury., J. Pharmacol. Exp. Ther.

NCI: VIOXX

Version: 14-September-2017

Alternate Names:

C1832 NCI drug code

Drug Info:

Publications:

Konturek et al., 2003, Influence of COX-2 inhibition by rofecoxib on serum and tumor progastrin and gastrin levels and expression of PPARgamma and apoptosis-related proteins in gastric cancer patients., Dig. Dis. Sci.

PharmGKB: rofecoxib

Version: 18-August-2020

Alternate Names:

Drug Info:

Publications:

Lee YS et al., 2006, Genetically mediated interindividual variation in analgesic responses to cyclooxygenase inhibitory drugs., Clin Pharmacol Ther

Grosser T, 2009, Variability in the response to cyclooxygenase inhibitors: toward the individualization of nonsteroidal anti-inflammatory drug therapy., J Investig Med

DTC: ROFECOXIB
- Version: 02-September-2020
Alternate Names:

CHEMBL122 ChEMBL Drug ID

Drug Info:

Publications:
TTD: Rofecoxib
- Version: 2020.06.01
Alternate Names:

D05VLS TTD Drug ID

Drug Info:

Publications:
GuideToPharmacology: 178100242
- Version: 29-September-2020
Alternate Names:

ROFECOXIB GuideToPharmacology Ligand Name

Drug Info:

Publications:
ChemblDrugs: chembl:CHEMBL122
- Version: ChEMBL_27
Alternate Names:

Drug Info:

Publications:
ChemblInteractions: CHEMBL122
- Version: chembl_23
Alternate Names:

Drug Info:

Publications:

Trial Name	rofecoxib,Vioxx
Novel drug target	Established target
Specific Action of the Ligand	Inhibition

ROFECOXIB Drug Record

ROFECOXIB chembl:CHEMBL122

Alternate Names:

Drug Info:

Publications:

ROFECOXIB PTGS2

Interaction Types & Directionality: inhibitor (inhibitory)

Interaction Info: Trial Name rofecoxib,Vioxx Novel drug target Established target Specific Action of the Ligand Inhibition

PMIDs: 19602986 16678543 20724158 10580458 10566562 20166930 10643177 11752352 11398914 10693877 18922570 10555907

Sources: TdgClinicalTrial ChemblInteractions GuideToPharmacology PharmGKB TTD

ROFECOXIB GHRL

Interaction Types & Directionality: n/a

Interaction Info:

PMIDs: 16868036

Sources: NCI

ROFECOXIB IL10

Interaction Types & Directionality: n/a

Interaction Info:

PMIDs: 15613743

Sources: NCI

ROFECOXIB BIRC5

Interaction Types & Directionality: n/a

Interaction Info:

PMIDs: 16707021 14627349

Sources: NCI

ROFECOXIB HSPB1

Interaction Types & Directionality: n/a

Interaction Info:

PMIDs: 16041694

Sources: NCI

ROFECOXIB BAX

Interaction Types & Directionality: n/a

Interaction Info:

PMIDs: 14627349

Sources: NCI

ROFECOXIB ALDH1A1

Interaction Types & Directionality: n/a

Interaction Info:

PMIDs: None found

Sources: DTC

TdgClinicalTrial: ROFECOXIB

Alternate Names:

Drug Info: Drug Indications NSAID Drug Class small molecule FDA Approval withdrawn

Publications:

NCI: ROFECOXIB

Alternate Names: C1832 NCI drug code

Drug Info:

NCI: VIOXX

Alternate Names: C1832 NCI drug code

Drug Info:

Publications: Konturek et al., 2003, Influence of COX-2 inhibition by rofecoxib on serum and tumor progastrin and gastrin levels and expression of PPARgamma and apoptosis-related proteins in gastric cancer patients., Dig. Dis. Sci.

PharmGKB: rofecoxib

Alternate Names:

Drug Info:

DTC: ROFECOXIB

Alternate Names: CHEMBL122 ChEMBL Drug ID

Drug Info:

Publications:

TTD: Rofecoxib

Alternate Names: D05VLS TTD Drug ID

Drug Info:

Publications:

GuideToPharmacology: 178100242

Alternate Names: ROFECOXIB GuideToPharmacology Ligand Name

Drug Info:

Publications:

ChemblDrugs: chembl:CHEMBL122

Alternate Names:

Drug Info:

Publications:

ChemblInteractions: CHEMBL122

Alternate Names:

Drug Info:

Publications:

Interaction Types & Directionality:

inhibitor (inhibitory)

Interaction Info:

Trial Name rofecoxib,Vioxx

Novel drug target Established target

Specific Action of the Ligand Inhibition

PMIDs:
19602986 16678543 20724158 10580458 10566562 20166930 10643177 11752352 11398914 10693877 18922570 10555907

Sources:
TdgClinicalTrial ChemblInteractions GuideToPharmacology PharmGKB TTD

Interaction Types & Directionality:

n/a

PMIDs:
16868036

Sources:
NCI

Interaction Types & Directionality:

n/a

PMIDs:
15613743

Sources:
NCI

Interaction Types & Directionality:

n/a

PMIDs:
16707021 14627349

Sources:
NCI

Interaction Types & Directionality:

n/a

PMIDs:
16041694

Sources:
NCI

Interaction Types & Directionality:

n/a

PMIDs:
14627349

Sources:
NCI

Interaction Types & Directionality:

n/a

PMIDs:
None found

Sources:
DTC

Drug Info:

Drug Indications NSAID

Drug Class small molecule

FDA Approval withdrawn

Alternate Names:

C1832 NCI drug code

Alternate Names:

C1832 NCI drug code

Publications:

Konturek et al., 2003, Influence of COX-2 inhibition by rofecoxib on serum and tumor progastrin and gastrin levels and expression of PPARgamma and apoptosis-related proteins in gastric cancer patients., Dig. Dis. Sci.

Alternate Names:

CHEMBL122 ChEMBL Drug ID

Alternate Names:

D05VLS TTD Drug ID

Alternate Names:

ROFECOXIB GuideToPharmacology Ligand Name